Claim check · Regulatory status, Product identity, Study interpretation

Evidence for an approved medicine and other products with the same peptide name

Claim (representative wording, not a quotation): Studies of an approved semaglutide medicine apply automatically to any product called semaglutide.

Plain-English answer

The trials behind an approved medicine tested that medicine. Their results carry over to another product only when a regulator has found the two equivalent, which is how an FDA-approved generic is judged against a named reference product. FDA states that compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before they are marketed, so such a product does not inherit the trial evidence through its name.

Verdict: Overstated. Part of the claim is supported, but the claim says more than the sources show: a wider population, a stronger outcome, a human result from animal work, or a certainty the design cannot give.

Scope

Population or organism
US-regulated injectable semaglutide (Wegovy) and liraglutide (Victoza as the reference product for an approved generic)
Study design
Comparison of an FDA-approved product label, FDA statements on compounded drugs, FDA requirements for generic drugs and an FDA approval record
Boundary
United States only, on the dates checked. It concerns whether trial evidence transfers, not the content, quality or safety of any specific product, which WPF did not test. It is not advice about any product, and regulatory status is not scientific evidence. Online "research" products are covered by the check on research-use-only labelling.

Strongest evidence

Regulatory decision

Product
Liraglutide injection (generic), ANDA215503, referencing Victoza
Indication
To lower blood sugar in patients with type 2 diabetes (as stated in the announcement title)
Jurisdiction
United States (FDA)
Decision type
Approval of a generic drug (abbreviated new drug application)
Decision date
2024-12-23
Official source
FDA announcement of the first generic referencing Victoza

Regulatory action is context, not scientific evidence about whether a product works.

What remains uncertain

  • These are regulator statements about status and process, not measurements of what any particular product contains or how it behaves.
  • FDA's wording on salt forms is conditional ("may be"). WPF did not verify how many products are salt forms.
  • FDA's statements describe compounded drugs as a category. They do not say any specific compounded product is unsafe or ineffective, and this check does not either.
  • The generic-drug page is general and not specific to liraglutide, and the approval announcement does not itself state the equivalence standard.
  • Other regulators' rules were not checked and can differ.

What would change the answer

  • Bioequivalence or clinical data for a specific non-approved product, which would speak to that product only.
  • An FDA approval of a product as a generic of a named reference product, which by FDA's description lets the reference product's evidence stand for it.
  • A change in FDA's published position on compounded products.

Exact gaps

  • The label was read on DailyMed (National Library of Medicine, which publishes FDA-submitted labels), not on Drugs@FDA.
  • Only one approved-generic example (liraglutide) was read in detail; WPF did not search for approved generics of other peptide medicines.
  • Products sold online as "research" peptides are not addressed here; see the research-use-only check.

Date checked and review status

Checked: · version 1.6.0

Review status: AI-assisted source verification. Human review: none recorded. Human review is pending and has not happened.

Profiles: /directory/semaglutide

Research journeys: /research/journey/semaglutide

What changed?: /research/changes#regulatory_decision

Cite this check

The citation names the version and an address that keeps returning what was checked, even after a newer version is published.

Evidence for an approved medicine and other products with the same peptide name: The trials behind an approved medicine tested that medicine. Their results carry over to another product only when a regulator has found the two equivalent, which is how an FDA-approved generic is judged against a named reference product. FDA states that compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before they are marketed, so such a product does not inherit the trial evidence through its name. Verdict: Overstated. Cited from World Peptide Foundation, Peptide Claims & Evidence, version 1.6.0, claim approved-medicine-evidence-same-peptide-name, checked 2026-11-14. AI-assisted source verification; human review none recorded.

Page:
https://www.worldpeptidefoundation.org/research/check/approved-medicine-evidence-same-peptide-name

Versioned record:
https://www.worldpeptidefoundation.org/api/research/claims/approved-medicine-evidence-same-peptide-name?version=1.6.0

Versioned record: /api/research/claims/approved-medicine-evidence-same-peptide-name?version=1.6.0